Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients
- Authors: Artamonova EV1, Kovalenko EI1, Snegovoy AV1, Aksarin AA2, Anciferova TA3, Belonogov AV4, Bilan EV5, Bilenko SN6, Varvus IM6, Gorkovenko EA7, Enikeev RF8, Ermolaeva AM9, Kramskaya LV10, Kononenko IB1, Pechenyy AP11, Safina SZ8, Chupriyanova TV12, Chuhua GG8, Shemyakina AI13, Shikina EV14
-
Affiliations:
- N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
- Surgut District Clinical Hospital
- City Polyclinic №195 of the Department of Health of Moscow
- Moscow City Oncological Hospital №62 of the Department of Health of Moscow
- District Clinical Hospital
- City Polyclinic №218 of the Department of Health of Moscow
- Elektrostal City Clinical Hospital
- Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstan
- Nizhny Novgorod Regional Clinical Oncologic Dispensary
- D.D.Pletnev City Clinical Hospital of the Department of Health of Moscow
- Orel Oncologic Dispensary
- Perm Regional Oncologic Dispensary
- Noginsk Central District Hospital
- Moscow Regional Clinical Oncologic Dispensary
- Issue: Vol 20, No 3 (2018)
- Pages: 19-25
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29560
- DOI: https://doi.org/10.26442/1815-1434_2018.3.19-25
- ID: 29560
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E V Artamonova
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Email: artamonovae@mail.ru
д-р мед. наук, зав. отд-нием химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
E I Kovalenko
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, науч. сотр. отд-ния амбулаторной химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A V Snegovoy
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, зав. отд-нием амбулаторной химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A A Aksarin
Surgut District Clinical Hospitalканд. мед. наук, рук. онкологического центра 628408, Russian Federation, Surgut, ul. Energetikov, d. 14
T A Anciferova
City Polyclinic №195 of the Department of Health of Moscowзав. отд-нием онкологии 121614, Russian Federation, Moscow, ul. Krylatskie holmy, d. 51
A V Belonogov
Moscow City Oncological Hospital №62 of the Department of Health of Moscowканд. мед. наук, зав. дневным стационаром №1 143423, Russian Federation, Moscow obl., pos. Istra, d. 27, str. 1-26
E V Bilan
District Clinical Hospitalзав. окружным онкологическим центром , г. Ханты-Мансийск, гл. внештатный специалист-онколог ДЗ ХМАО-Югры 628012, Russian Federation, Khanty-Mansiysk, ul. Kalinina, d. 40
S N Bilenko
City Polyclinic №218 of the Department of Health of Moscowврач-онколог 127642, Russian Federation, Moscow, pr. Shokalskogo, d. 8
I M Varvus
City Polyclinic №218 of the Department of Health of Moscowврач-онколог 127642, Russian Federation, Moscow, pr. Shokalskogo, d. 8
E A Gorkovenko
Elektrostal City Clinical Hospitalврач-гинеколог 144000, Russian Federation, Moscow obl., Elektrostal, ul. Pushkina, d. 3
R F Enikeev
Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstanканд. мед. наук, врач-онколог 420029, Russian Federation, Kazan, ul. Sibirskiy trakt, d. 29
A M Ermolaeva
Nizhny Novgorod Regional Clinical Oncologic Dispensaryзав. химиотерапевтическим отд-нием 603093, Russian Federation, Nizhny Novgorod, ul. Delovaia, d. 11/1
L V Kramskaya
D.D.Pletnev City Clinical Hospital of the Department of Health of Moscowзав. 3-м онкологическим отд-нием 105077, Russian Federation, Moscow, ul. 11-ia Parkovaia, d. 32
I B Kononenko
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, ст. науч. сотр. отд-ния амбулаторной химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A P Pechenyy
Orel Oncologic Dispensaryканд. мед. наук, врач-онколог, поликлиническое отд-ние 302020, Russian Federation, Orel, per. Ippodromnii, d. 2
S Z Safina
Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstanканд. мед. наук, зав. отд. химиотерапии 420029, Russian Federation, Kazan, ul. Sibirskiy trakt, d. 29
T V Chupriyanova
Perm Regional Oncologic Dispensaryзам. глав. врача 614066, Russian Federation, Perm, ul. Baumana, d. 15
G G Chuhua
Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstanврач-онколог, отд-ние химиотерапии №3 420029, Russian Federation, Kazan, ul. Sibirskiy trakt, d. 29
A I Shemyakina
Noginsk Central District Hospitalврач-онкогинеколог 142400, Russian Federation, Moscow obl., Noginsk, Komsomolskaia ul., d. 59
E V Shikina
Moscow Regional Clinical Oncologic Dispensaryканд. мед. наук, зав. химиотерапевтическим отд-нием дневного стационара 143900, Russian Federation, Moscow obl., Balashiha, ul. Karbysheva, d. 6
References
- http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf (GLOBOCAN 2008 (IARC). Section of Cancer Information (6/3/2011); p. 3-7.
- Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М., 2017.
- Press J.Z, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
- Любченко Л.Н., Бартенева Е.И., Абрамов И.С. и др. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013; 2: 53-61.
- Daniels M.S, Babb S.A, King R.H et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol 2014; 32: 1249-55.
- Hamel N et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011; 19 (3): 300-6.
- Patel J.N. Differences in pharmacology, toxicities key to clinical use of PARP inhibitors. HemOnc Today, March 10, 2018.
- Farmer H, McCabe N, Lord C.J et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
- Bryant H.E, Schultz N, Thomas H.D et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
- Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-25.
- Fong P.C, Boss D.S, Yap T.A et al. Inhibitions of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Eng J Med 2009. DOI: 10.1056;NEJMoa0900212
- Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-92.
- Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-61.
- Ledermann J.A, Harter P, Gourley C et al. Overall sur-vival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. J Clin Oncol 2016; 34 (Suppl. 15): abst 5501.
- Lederman J.A, Harter Ph, Gourley Ch et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 2016; 16 (11): 1579-89.
- Pujade-Lauraine E, Lederman J.A, Selle F et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2017; 18 (9): 1274-84.
- Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v4.02. 2009. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
- Therasse P, Arbuck S.G, Eisenhauer E.A et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.